At the time of writing, Emergent Biosolutions Inc [EBS] stock is trading at $6.67, down -1.19%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EBS shares have gain 5.37% over the last week, with a monthly amount glided 14.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Emergent Biosolutions Inc [NYSE: EBS] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $15. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 22, 2024, and set its price target to $16. On March 07, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. The Benchmark Company downgraded its rating to a Hold. The Benchmark Company upgraded its rating to Buy for this stock on April 10, 2023, but kept the price target unchanged to $22. In a note dated March 17, 2023, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $23 to $9.
For the past year, the stock price of Emergent Biosolutions Inc fluctuated between $4.02 and $15.10. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Emergent Biosolutions Inc [NYSE: EBS] shares were valued at $6.67 at the most recent close of the market. An investor can expect a potential return of 672.11% based on the average EBS price forecast.
Analyzing the EBS fundamentals
According to Emergent Biosolutions Inc [NYSE:EBS], the company’s sales were 965.40M for trailing twelve months, which represents an -26.03% plunge. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.27 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.56 points at the first support level, and at 6.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.84, and for the 2nd resistance point, it is at 7.02.
Ratios To Look Out For
It is important to note that Emergent Biosolutions Inc [NYSE:EBS] has a current ratio of 6.32. In addition, the Quick Ratio stands at 3.51 and the Cash Ratio stands at 1.33. Considering the valuation of this stock, the price to sales ratio is 0.38, the price to book ratio is 0.66.
Transactions by insiders
Recent insider trading involved Katkin Keith, Director, that happened on May 23 ’25 when 7844.0 shares were sold. Director, KEITH KATKIN completed a deal on May 23 ’25 to buy 7844.0 shares. Meanwhile, President and CEO PAPA JOSEPH C bought 60000.0 shares on May 13 ’25.
